Company Overview and News
Matrix Concepts Holdings Bhd (Oct 4, RM2.06) Maintain buy with an unchanged target price of RM2.21: Matrix Concepts Holdings Bhd has entered into a joint venture (JV) agreement (30% stake) for the joint development of the Islamic financial district in PIK2, Jakarta. Overall, we are positive on the JV as this may lead to more opportunities to expand in Indonesia by leveraging the expertise and connections of the respective partners.
KUALA LUMPUR (Oct 3): The FBM KLCI is seen hovering below the 1,800-point level today,tracking the overnight close at most gobal markets, exacerbated by tepid local investor sentiment.
0078 0143 5236 7811 MGFCF MSCI 9113
KUALA LUMPUR (Oct 2): Based on corporate announcements and news flow today, companies in focus on Wednesday (Oct 3) may include: Key ASIC Bhd, GD Express Carrier Bhd, Malakoff Corp Bhd, DRB-Hicom Bhd, Malaysia Marine and Heavy Engineering Holdings Bhd, Malton Bhd, Matrix Concepts Holdings Bhd, Mega First Corp Bhd, Sanbumi Holdings Bhd and Sapura Industrial Bhd.
0078 0143 5236 7811 MGFCF 9113
Matrix Concepts Holdings Bhd (Aug 28, RM2.10) Maintain buy with an unchanged target price (TP) of RM2.21: Matrix Concepts Holdings Bhd’s revenue for first quarter of financial year 2019 (1QFY19) of RM230 million translated into a core profit after tax and minority interest of RM50.2 million, which came in below our expectations, accounting for 17.7% and 20.1% of our and consensus full-year forecasts, respectively.
KUALA LUMPUR: Matrix Concepts Holdings Bhd’s founder and major shareholder Datuk Lee Tian Hock has been redesignated as the group’s executive deputy chairman effective Sept 1.
KUALA LUMPUR: Vertice Bhd, Daiman Development Bhd , Padini Holdings Bhd , Matrix Concepts Holdings Bhd and IOI Properties Group Bhd are among the stocks to watch, according to JF Apex Research.
5249 9385 7052 5236 5355
KUALA LUMPUR (Aug 27): Based on corporate announcements and news flow today, stocks in focus on Tuesday (Aug 28) may include Daiman Development Bhd, Gamuda Bhd, Taliworks Corp Bhd, Top Glove Corp Bhd, Matrix Concepts Holdings Bhd, Vertice Bhd, BIMB Holdings Bhd, IOI Properties Group Bhd, Utusan Melayu (Malaysia) Bhd, WCT Holdings Bhd and Watta Holding Bhd.
7240 7113 TPGVF 9679 7226 5355 TGLVY 5249 5754 5258 5236 BSMAF 1818
KUALA LUMPUR (Aug 27): Matrix Concepts Holdings Bhd's founder and major shareholder, Datuk Lee Tian Hock, has been redesignated as the group's executive deputy chairman.
5236 BSMAF 1818
KUALA LUMPUR (Aug 27): Matrix Concepts Holdings Bhd's net profit grew 10.1% to RM50.15 million in the first financial quarter ended June 30, 2018 (1QFY19), from RM45.55 million a year ago, on higher revenue recognition of projects under construction worth RM2.3 billion in gross development value (GDV).
Matrix Concepts Holdings Bhd chairman Datuk Mohamad Haslah Mohamad Amin (second from right) and members of his team reading the company's annual report before the annual general meeting. From left are group deputy managing director Ho Kong Soon, managing director Datuk Lee Tian Hock and director Datuk N.Logendran. - UU BAN/The Star
THE property market is still soft with most developers experiencing slow sales. Most property developers, it seems, are taking a cautiously optimistic view of the market in the near term. According to some of the developers participating in EdgeProp.my’s Malaysia Virtual Property Expo (VPEX) 2018, the days ahead will remain challenging but they are feeling a tad more optimistic of the future than before.
5789 5148 5236 7066
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...